^
Association details:
| Biomarker: | TMB-H + MSH6 F1088fs |
|---|---|
| Cancer: | Ovarian Serous Adenocarcinoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A durable response to pembrolizumab in a patient with uterine serous carcinoma and Lynch syndrome due to the MSH6 germline mutation
Published date:
05/20/2021
Excerpt:
...a case of metastatic uterine serous carcinoma due to a germline MSH6 mutation (Lynch syndrome) which was discovered because of her tumor MMR deficiency. The patient was started on first-line pembrolizumab in 2018 and sustained a partial response. She remains asymptomatic and progression-free for more than two years. Tumor sequencing showed a high mutational burden and an upstream somatic mutation in the same gene, p.F1088fs.
DOI:
https://doi.org/10.1002/onco.13832
